Bicycle Therapeutics plc 50BA.F Stock
Bicycle Therapeutics plc Price Chart
Bicycle Therapeutics plc 50BA.F Financial and Trading Overview
Bicycle Therapeutics plc stock price | 19.4 EUR |
Previous Close | 23.6 EUR |
Open | 23.2 EUR |
Bid | 23.4 EUR x N/A |
Ask | 25.4 EUR x N/A |
Day's Range | 23.2 - 23.2 EUR |
52 Week Range | 15.2 - 30 EUR |
Volume | 500 EUR |
Avg. Volume | 17 EUR |
Market Cap | 718.46M EUR |
Beta (5Y Monthly) | 0.733901 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -4.05 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 54.64 EUR |
50BA.F Valuation Measures
Enterprise Value | 464.68M EUR |
Trailing P/E | N/A |
Forward P/E | -5.2847385 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 46.355396 |
Price/Book (mrq) | 2.8652587 |
Enterprise Value/Revenue | 29.981 |
Enterprise Value/EBITDA | -3.681 |
Trading Information
Bicycle Therapeutics plc Stock Price History
Beta (5Y Monthly) | 0.733901 |
52-Week Change | 33.33% |
S&P500 52-Week Change | 20.43% |
52 Week High | 30 EUR |
52 Week Low | 15.2 EUR |
50-Day Moving Average | 20.2 EUR |
200-Day Moving Average | 23.65 EUR |
50BA.F Share Statistics
Avg. Volume (3 month) | 17 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 30.04M |
Float | 20.05M |
Short Ratio | N/A |
% Held by Insiders | 9.86% |
% Held by Institutions | 89.10% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -845.68% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -18.44% |
Return on Equity (ttm) | -43.32% |
Income Statement
Revenue (ttm) | 15.5M EUR |
Revenue Per Share (ttm) | 0.52 EUR |
Quarterly Revenue Growth (yoy) | 26.80% |
Gross Profit (ttm) | -67146000 EUR |
EBITDA | -126249000 EUR |
Net Income Avi to Common (ttm) | -124217000 EUR |
Diluted EPS (ttm) | -3.82 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 293.82M EUR |
Total Cash Per Share (mrq) | 9.78 EUR |
Total Debt (mrq) | 49.47M EUR |
Total Debt/Equity (mrq) | 20.34 EUR |
Current Ratio (mrq) | 7.194 |
Book Value Per Share (mrq) | 8.097 |
Cash Flow Statement
Operating Cash Flow (ttm) | -106122000 EUR |
Levered Free Cash Flow (ttm) | -119008376 EUR |
Profile of Bicycle Therapeutics plc
Country | Germany |
State | N/A |
City | Cambridge |
Address | Portway Building |
ZIP | CB21 6GS |
Phone | 44 1223 261 503 |
Website | https://www.bicycletherapeutics.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 236 |
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. It is developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; BT5528, a BTC that is in a Phase I/II clinical trial targeting Ephrin type-A receptor 2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. The company also develops THR-149, a plasma kallikrein inhibitor for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA; and BT7401, a multivalent CD137 agonist. In addition, it collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, dementia, central nervous system, neuromuscular, and respiratory indications. The company has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca AB, Sanofi, Oxurion NV, and the Dementia Discovery Fund, as well as with Ionis Pharmaceuticals, Inc.; and a discovery collaboration and license agreement with Genentech Inc. for the discovery and development of Bicycle peptides for multiple immuno-oncology targets, as well as strategic collaboration with Bayer for developing Novel Targeted Radionuclide Therapies in Oncology. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.
Q&A For Bicycle Therapeutics plc Stock
What is a current 50BA.F stock price?
Bicycle Therapeutics plc 50BA.F stock price today per share is 19.4 EUR.
How to purchase Bicycle Therapeutics plc stock?
You can buy 50BA.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Bicycle Therapeutics plc?
The stock symbol or ticker of Bicycle Therapeutics plc is 50BA.F.
Which industry does the Bicycle Therapeutics plc company belong to?
The Bicycle Therapeutics plc industry is Biotechnology.
How many shares does Bicycle Therapeutics plc have in circulation?
The max supply of Bicycle Therapeutics plc shares is 39.59M.
What is Bicycle Therapeutics plc Price to Earnings Ratio (PE Ratio)?
Bicycle Therapeutics plc PE Ratio is now.
What was Bicycle Therapeutics plc earnings per share over the trailing 12 months (TTM)?
Bicycle Therapeutics plc EPS is -4.05 EUR over the trailing 12 months.
Which sector does the Bicycle Therapeutics plc company belong to?
The Bicycle Therapeutics plc sector is Healthcare.